322 related articles for article (PubMed ID: 31100462)
1. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
2. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
[TBL] [Abstract][Full Text] [Related]
4. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
Zhang C; An T; Wang D; Wan G; Zhang M; Wang H; Zhang S; Li R; Yang X; Wang Y
J Control Release; 2016 Mar; 226():193-204. PubMed ID: 26896737
[TBL] [Abstract][Full Text] [Related]
5. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma.
Wang Y; Chen H; Liu Y; Wu J; Zhou P; Wang Y; Li R; Yang X; Zhang N
Biomaterials; 2013 Sep; 34(29):7181-90. PubMed ID: 23791500
[TBL] [Abstract][Full Text] [Related]
6. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
7. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
[TBL] [Abstract][Full Text] [Related]
8. Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus.
Yu H; Shen N; Bao Y; Chen L; Tang Z
Biomater Sci; 2020 Jan; 8(1):325-332. PubMed ID: 31714543
[TBL] [Abstract][Full Text] [Related]
9. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Bian Y; Guo D
Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
[TBL] [Abstract][Full Text] [Related]
11. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
12. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
[TBL] [Abstract][Full Text] [Related]
13. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
[TBL] [Abstract][Full Text] [Related]
16. Formula optimization and in vivo study of poly(L-glutamic acid)-g-methoxy poly(ethylene glycol)/combretastatin A4/BLZ945 nanoparticles for cancer therapy.
Huang Y; Yang C; Lv J; Zhang Y; Wang K; Ma L; Liu Z; Yu H; Li M; Tang Z
Int J Pharm; 2023 Apr; 636():122849. PubMed ID: 36933582
[TBL] [Abstract][Full Text] [Related]
17. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Li M; Su Y; Zhang F; Chen K; Xu X; Xu L; Zhou J; Wang W
Acta Biomater; 2018 Jul; 75():413-426. PubMed ID: 29859368
[TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Wang H; Zhang C; Chi H; Meng Z
Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination.
El Shorbagy S; abuTaleb F; Labib HA; Ebian H; Harb OA; Mohammed MS; Rashied HA; Elbana KA; Haggag R
J Gastrointest Cancer; 2021 Mar; 52(1):269-279. PubMed ID: 32212089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]